Brief: Poolbeg Pharma Says POLB 001 Treatment Exhibited Marked Reduction In Multiple Markers Of Systemic And Local Inflammation
02/03/2023 08:15
March 2 (Reuters) - Poolbeg Pharma PLC POLB.L :
* POOLBEG PHARMA PLC - ANNOUNCES DATA READOUT FROM BACTERIAL
LIPOPOLYSACCHARIDE HUMAN CHALLENGE TRIAL FOR POLB 001
* POOLBEG PHARMA PLC - POLB 001 RESULTED IN A HIGHLY
SIGNIFICANT
REDUCTION IN P38 MAP KINASE DRIVEN CYTOKINES
* POOLBEG PHARMA PLC - POLB 001 TREATMENT EXHIBITED MARKED
REDUCTION IN MULTIPLE MARKERS OF SYSTEMIC AND LOCAL INFLAMMATION
COMPARED WITH PLACEBO
* POOLBEG PHARMA PLC - TRIAL RESULTS DEMONSTRATE EXPECTED
UTILITY
IN SEVERE INFLUENZA AND OTHER ACUTE INFLAMMATORY CONDITIONS
* POOLBEG PHARMA -POLB 001 SHOWN TO BE SAFE & WELL
TOLERATED,HAD
POTENT EFFECT IN SYSTEMIC & LOCALISED INFLAMMATORY RESPONSE IN A
DOSE DEPENDENT MANNER
Source text for Eikon: ID:nRSB6481Ra
Further company coverage: POLB.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Poolbeg Pharma
See all newsBrief: Poolbeg Pharma Says European Patent Granted For POLB 001 In CRS
PDMR Notification
Brief: Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001
Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
Annual Report & AGM Notice